Alumis Inc. (ALMS) company profile
Close on Nov 17, 2026Market cap $626.47MP/E –Yield –
About Alumis
Pharmaceutical Preparations, SIC 2834
Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing targeted oral therapies to replace broad immunosuppression for patients with immune-mediated conditions. The company's lead product candidate is envudeucitinib, an allosteric Tyrosine Kinase 2 (TYK2) inhibitor being evaluated for plaque psoriasis and systemic lupus erythematosus. Its pipeline also includes A-005, a central nervous system-penetrant TYK2 inhibitor aimed at neuroinflammatory and neurodegenerative disorders, alongside lonigutamab, a monoclonal antibody targeting IGF-1R for thyroid eye disease acquired via its merger with ACELYRIN.
The company operates without internal manufacturing facilities, outsourcing clinical-stage production and supply of active pharmaceutical ingredients and raw materials to third-party contract manufacturers located internationally, including in India and Taiwan. Its clinical trials and patent protections span across the United States, Europe, the United Kingdom, Latin America, and Asia-Pacific countries. The provided text does not disclose the specific location of its corporate headquarters.
Summary of the business section of Alumis's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Alumis Inc.
- Founded
- 2021
- Headquarters
- South San Francisco, CA
- Address
- 280 East Grand Avenue 94080
- Phone
- (650) 231-6625
- Website
- alumis.com
- Employees
- 224, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, San Jose, California
Stock & identifiers
- Ticker
- ALMS
- Exchange
- Nasdaq
- IPO date
- Jun 28, 2024
- Shares outstanding
- 129M, Aug 6, 2026
- Public float
- $183.20M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1847367
- CUSIP
- 022307102
- ISIN
- US0223071020
- FIGI
- BBG01J7X4PN2
- Share class FIGI
- BBG01J7X4PP0
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Martin Babler | President, CEO and Chairman, Director | 109,454 |
| Sanam Pangali | Chief Legal Officer | 9,415 |
| Mark Christopher Bradley | Chief Development Officer | 67,936 |
| John R. Schroer | Chief Financial Officer | 23,924 |
| Roy C. Hardiman | Chief Business & Strategy Ofcr | 213,511 |
| David M. Goldstein | Chief Scientific Officer | 247,572 |
| Jorn Drappa | Chief Medical Officer | 56,299 |
| Derrick Richardson | SVP, People and Culture | 42,800 |
| Sara Klein | Chief Legal Officer | 33,796 |
| Srinivas Akkaraju | Director | 6,966,072 |
| Patrick Machado | Director | 10,617 |
| Lynn A. Tetrault | Director | 3,553 |
| Sapna Srivastava | Director | 3,553 |
| Zhengbin Yao | Director | 27,082 |
| James B. Tananbaum | Director | 1,123,337 |
| David E. Goel | Director | 10,645,966 |
| AyurMaya Capital Management Company, LP | Director | 15,139,707 |
| Alan Colowick | Director | 18,404 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Incentive pay | Total | vs. prior year |
|---|---|---|---|---|---|
| Martin Babler President, Chief Executive Officer, and Chairman of the Board | $680.83K | $4.74M | $524.24K | $5.95M | -44% |
| David M. Goldstein, Ph.D. Chief Scientific Officer | $526.40K | $1.19M | $294.79K | $2.01M | -38% |
| Jörn Drappa, M.D., Ph.D. Chief Medical Officer | $523.76K | $1.16M | $293.30K | $1.98M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jun 28, 2024
- Offer price
- $16.00
- Securities offered
- 13,125,000
- Gross proceeds
- $210.00M
- Exchange
- Nasdaq
- First trading day
- Jun 28, 2024
- First-day close
- $13.30-16.9%
- Lock-up ends (est.)
- Dec 25, 2024
“The initial public offering price per share is $16.00.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed 221 full-time and 3 part-time employees, consisting of clinical, scientific, development, regulatory, finance, legal and operational personnel. We also retain ”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 21, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Apr 21, 2025 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Mar 27, 2025 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Jun 28, 2024 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 25, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |
| Mar 19, 2021 | Name change | Name changed from FL2021-001, Inc. to Alumis Inc. |
See a number that looks wrong?